Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia, Psychotic Disorders
A Registry of Treatment Adherence for Patients With Schizophrenia
The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second…
- Trial name
- NCT00283517
- Testing
- antipsychotics
- Volunteers
- 2,046 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
This study is aimed to evaluate the bipolar disorder symptoms in patients presented with schizophrenia, schizoaffective disorder or recurrent depression.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Recurrent Depression
- Trial name
- NCT01028196
- Where
- 3 sites in Russia
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Encephalopathy, Psychosis
Neuroimmunology Registry and Biobank
A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases.
- Conditions
- Encephalopathy, Psychosis, Impaired Consciousness, Epilepsy
- Trial name
- NCT06958341
- Where
- 2 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia
Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia
This study will evaluate the long-term real-world safety of xanomeline-trospium chloride in adults with schizophrenia receiving routine clinical care in the United States.
- Trial name
- NCT07783373
- Testing
- xanomeline-trospium chloride, Oral antipsychotics
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
The purpose of the study is to investigate these effects of Second-Generation Antipsychotic (SGAs) on glucose and lipid metabolic parameters in patients with schizophrenia, and explore the relationship between genes polymorphisms…
- Trial name
- NCT02964923
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital
Schizophrenia, Schizoaffective Disorder
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and…
- Trial name
- NCT02417142
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Massachusetts, Worcester
Indication for Modification of Patient Cognitive Status
Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia
The purpose of this study was to develop an integrative intervention for schizophrenia taking into account previous efficacious therapies.
- Trial name
- NCT01279070
- Testing
- Repyflec cognitive remediation training
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia
Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia
This multicenter, randomized, open-label, parallel-group, multiple-dose study is designed to evaluate the bioequivalence, at pharmacokinetic steady state, of a paliperidone palmitate injection manufactured by CSPC Zhongnuo…
- Trial name
- NCT07268430
- Testing
- Paliperidone Palmitate Injection(PP1M), Paliperidone Palmitate Injection(PP1M)(Reference Group)
- Where
- China
- Volunteers
- 256 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Schizophrenia
eMotiph: E-mental Health Solution for Patients With Schizophrenia
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%.
- Trial name
- NCT05345977
- Testing
- eMotiph
- Where
- Spain
- Volunteers
- 7 people
- Sponsor
- Grupo Pulso
Schizophrenia
tDCS, Stress and Risk for Schizophrenia
An exacerbated response to stress mediated by activation of the Hypothalamo-Pituitary-Adrenocortical (HPA) axis is thought to play an important role in the onset, worsening and relapse of schizophrenia.
- Trial name
- 3S (NCT03217357)
- Testing
- Transcranial stimulation in direct current
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Hôpital le Vinatier
Schizophrenia
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
A clinical study to investigate the long-term safety and torelability of SEP-363856 in clinically stable adult patients with schizophrenia in Japan.
- Trial name
- NCT05359081
- Testing
- SEP-363856
- Where
- 51 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia Disorder, Cognitive Impairments
TIS for Improving Cognitive Impairment in Schizophrenia
This study aims to evaluate the efficacy, safety, and underlying neural mechanisms of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS).
- Trial name
- NCT07647380
- Testing
- temporal interference stimulation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Central South University
Schizophrenia
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT04825860
- Testing
- SEP-363856 50 mg, SEP-363856 75 mg
- Where
- 54 sites in China, Japan and 2 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia, Hallucinations
Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations
This study will evaluate the long-term effects of repetitive transcranial magnetic stimulation (rTMS) in patients with auditory hallucinations.
- Trial name
- NCT00042159
- Testing
- repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846868
- Testing
- Iclepertin
- Where
- 116 sites in United States, Australia and 15 more
- Volunteers
- 620 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Bipolar Disorder
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Trial name
- NCT06229210
- Testing
- Lumateperone
- Where
- 65 sites in United States, Colombia and 1 more
- Volunteers
- 300 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Refractory Schizophrenia
Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia
Primary Objective: Efficacy of Occupational Therapy (OT) based Occupational Goal Intervention (OGI) in improving executive functions in patients with refractory schizophrenia as measured by the BADS.
- Trial name
- OTSchizo (NCT01879956)
- Testing
- Craft Activities, OGI Method
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Schizophrenia
Coaching Intervention for Patients With Early Psychosis
Jockey Club Early Psychosis (JCEP) project is a territory-wide specialized EI service that is launched in August 2009 and provides 3-year phase-specific intervention for adult patients presenting with first-episode psychosis…
- Trial name
- NCT01792856
- Testing
- Recovery-oriented intervention, psychoeducation
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The University of Hong Kong
Schizophrenia
A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia
The purpose of this study will be to evaluate the safety and treatment response of paliperidone palmitate administered to Chinese patients with schizophrenia.
- Trial name
- NCT01947803
- Testing
- Paliperidone Palmitate
- Where
- 12 sites in China
- Volunteers
- 353 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia, Cognitive Impairment
Functional Magnetic Resonance Imaging Study in Schizophrenia Patients and Correlation With Cognitive Impairments
1. Comparison of functional activity at different brain areas related to different cognitive domains e.g. Memory, visuospatial abilities, executive functions, attention, concentration, language, orientation in schizophrenia to…
- Trial name
- NCT06471179
- Testing
- Functional MRI
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.